Inspire Medical Systems (STU:2DR) Current Deferred Revenue: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2DR Inspire Medical Systems Inc STU:2DR
63 GF Score
Price €51.00
GF Value €171.65
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Inspire Medical Systems Current Deferred Revenue?

Inspire Medical Systems STU:2DR -0.97% 63 Current Deferred Revenue is €0.0 Mil as of Jun. 2026. GuruFocus rates STU:2DR with a GF Score™ of 63/100 and a GF Value™ of €171.65 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Inspire Medical Systems's current deferred revenue for the quarter that ended in Jun. 2026 was €0.0 Mil.

Inspire Medical Systems Current Deferred Revenue Related Terms

Inspire Medical Systems Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Inspire Medical Systems's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inspire Medical Systems Current Deferred Revenue Chart

Inspire Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Inspire Medical Systems Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:2DR
63GF Score
Inspire Medical Systems Inc STU:2DR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.0 Mil mean?
Inspire Medical Systems (STU:2DR) has a Current Deferred Revenue of €0.0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Inspire Medical Systems and its competitors.
Is Inspire Medical Systems' Current Deferred Revenue too high?
Inspire Medical Systems' current Current Deferred Revenue is €0.0 Mil. Overall, Inspire Medical Systems has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Inspire Medical Systems' Current Deferred Revenue compare to AHCO and IART?
Inspire Medical Systems' Current Deferred Revenue of €0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Inspire Medical Systems and its competitors. Inspire Medical Systems's current Current Deferred Revenue is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Inspire Medical Systems (STU:2DR) is currently considered Significantly Undervalued. The stock's GF Value™ is €171.65, compared to a current price of €51.00 — trading 70.3% below its estimated fair value. The current Current Deferred Revenue is €0.0 Mil. Inspire Medical Systems' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Inspire Medical Systems (STU:2DR), the current Current Deferred Revenue is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inspire Medical Systems (STU:2DR) Overvalued in 2026?

Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued. The current stock price of €51.00 is trading 70.3% below its estimated GF Value™ of €171.65. GuruFocus considers Inspire Medical Systems to be Significantly Undervalued.

Key valuation signals for STU:2DR:

  • Current Deferred Revenue: €0.0 Mil
  • GF Value™: €171.65 vs. price of €51.00 (70.3% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the STU:2DR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inspire Medical Systems Business Description

Other Exchanges INSP:USA
Address 5500 Wayzata Boulevard, Suite 1600, Golden Valley, MN, USA, 55416
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
63GF Score

Get the complete analysis for STU:2DR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.00
Price
€171.65
GF Value